Hypoglycemia is the major barrier to good glycemic control in patients with diabetes mellitus. Furthermore, randomized controlled trials have emphasized the grave risks associated with severe ...

The FDA has granted Orphan Drug designation to ersodetug (RZ358) for the treatment of hypoglycemia due to tumor hyperinsulinism.

Rezolute received an orphan-drug designation from the Food and Drug Administration for its treatment of hypoglycemia, or low blood sugar, caused by a disease in which a tumor produces too much insulin ...